Results 211 to 220 of about 46,559 (243)
Some of the next articles are maybe not open access.
Pharmacotherapy of benign prostatic hyperplasia: Inhibitor of 5 alpha-reductase
International Urology and Nephrology, 1997We studied the effects of 5 alpha-reductase inhibitor (finasteride) in the treatment of benign prostatic hyperplasia (BPH). This study is a randomized controlled trial. Sixty-two patients were treated with 5 alpha-reductase (finasteride 5 mg/day) and 61 patients (control group) with placebo for one year.
BAYRAKTAR, YILMAZ +4 more
openaire +3 more sources
[5-alpha-reductase inhibitors].
Acta urologica Belgica, 1995A reflection is made, on the one hand, on the lack of correlation between the intensity of micturition problems and the volume of the prostate and, on the other hand, on the different therapeutic approaches of irritative or obstructive voiding problems, and finally on the insufficiently convincing activity of Finasteride.
K, De Jaegher, P, Kozyreff, H, Claes
openaire +1 more source
Finasteride: the first 5 alpha-reductase inhibitor.
Pharmacotherapy, 1993Finasteride is a synthetic 4-azasteroid that is a specific competitive inhibitor of 5 alpha-reductase, an intracellular enzyme that converts testosterone to dihydrotestosterone (DHT). It has no binding affinity for androgen receptor sites and itself possesses no androgenic, antiandrogenic, or other steroid hormone-related properties.
S L, Sudduth, M J, Koronkowski
openaire +2 more sources
Side Effects of 5‐Alpha Reductase Inhibitors: A Comprehensive Review
Sexual Medicine Reviews, 20135α-reductase inhibitors (5ARI) include finasteride and dutasteride, and are commonly prescribed in the treatment of benign prostatic hyperplasia and androgenic alopecia. 5ARIs are associated with several known adverse effects (AEs), with varying reported prevalence rates.The aim was to review and summarize findings from published literature detailing ...
Landon, Trost +2 more
openaire +2 more sources
Prostate cancer prevention with 5-alpha reductase inhibitors
Current Opinion in Urology, 2018We review the concepts surrounding prostate cancer prevention strategies with 5-alpha reductase inhibitors (5-ARIs) and the controversies associated with their use.Updated data have shown no increased risk of death from the diagnosis of higher risk cancer; however, 5-ARIs remain controversial and not approved for prostate cancer prevention.The main ...
Michael A, Liss, Ian M, Thompson
openaire +2 more sources
Prostate Cancer Prevention with 5 Alpha-Reductase Inhibitors
2010Testosterone gets converted into the more potent 5-[alpha]-dihydrotestosterone by 5-[alpha]- reductase. dihydrotestosterone (DHT) controls prostate mitotic activity and potentially prostate carcinogenesis. Interventions that inhibit 5-[alpha]-reductase have potential as preventive agents for prostate cancer.
openaire +2 more sources
Novel aromatase and 5α-reductase inhibitors
The Journal of Steroid Biochemistry and Molecular Biology, 1994Inhibitors of aromatase and 5 alpha-reductase may be of use for the therapy of postmenopausal breast cancer and benign prostatic hyperplasia, respectively. FCE 27993 is a novel steroidal irreversible aromatase inhibitor structurally related to exemestane (FCE 24304).
E, Di Salle +7 more
openaire +2 more sources
Finasteride: a 5 alpha-reductase inhibitor.
Clinical pharmacy, 1993The pharmacology and pharmacokinetics of finasteride are reviewed, and finasteride's clinical efficacy, adverse effects, and dosage in patients with benign prostatic hyperplasia (BPH) are described. Finasteride is a member of a new class of medications, the azasteroids, that have antiandrogenic activity limited to certain tissues, including the ...
openaire +1 more source
5-Alpha Reductase Inhibitors in Prostate Cancer
2010Androgenic effects in prostate cancer cells depend on the synthesis and metabolism of hormones and the presence of androgen receptor. 5-alpha reductase isoenzymes I and II differ in chromosomal localization, pH optimum, enzyme kinetics, and expression in benign and malignant prostate tissue.
openaire +1 more source
Long-Term Experience with 5-alpha-Reductase Inhibitors.
Reviews in urology, 2011Finasteride, a 5-alpha-reductase inhibitor, dramatically suppresses the production of dihydrotestosterone in men; thus, attention has turned to this agent for the treatment of benign prostatic hyperplasia (BPH). A number of randomized clinical trials have studied finasteride's effects on prostate size, BPH symptoms, flow rate, and prostate-specific ...
openaire +2 more sources